William Ross
Cardiovascular Disease · Tulsa, OKNPI 1619976776
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.0% of the total across 182 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 24 manufacturers, the largest accounting for just 15.3% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $2,455 and has fallen 98.4% since, to $39 in 2021. That places this record below the midpoint for cardiovascular disease clinicians in OK, where the typical reported total is $2,806.
Across 182 payments — averaging $15.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$442
- Johnson & Johnson$278
- Biotronik Inc.$197
- AstraZeneca$164
- E.r. Squibb & Sons, L.L.C.$157
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$157
- plus $1K from 18 others
What the payments were for
- Food & beverage$2,85499%
- Education$291%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 25 | $442 |
| Johnson & Johnson | 18 | $278 |
| Biotronik Inc. | 11 | $197 |
| AstraZeneca | 13 | $164 |
| E.r. Squibb & Sons, L.L.C. | 13 | $157 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 12 | $157 |
| Sanofi-aventis U.S. LLC | 10 | $154 |
| Novartis | 12 | $139 |
| Boehringer Ingelheim | 11 | $137 |
| Boston Scientific | 8 | $126 |
| Kowa Pharmaceuticals America, Inc. | 10 | $122 |
| Regeneron Healthcare Solutions, Inc. | 7 | $120 |
| UCB, Inc. | 1 | $117 |
| Abbott | 5 | $116 |
| Amarin Pharma, Inc. | 6 | $102 |
| Lundbeck LLC | 5 | $96 |
| Pfizer | 5 | $63 |
| Angiodynamics, Inc. | 1 | $49 |
| Arbor Pharmaceuticals, Inc. | 3 | $38 |
| Chiesi USA, Inc. | 2 | $38 |
| Cook Medical LLC | 1 | $28 |
| Nuwellis, Inc. | 1 | $17 |
| Medtronic | 1 | $14 |
| Gilead | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Cimzia$117
How this compares
$2,883 in reported general payments places this provider in the 50th percentile of 164 cardiovascular disease providers in Oklahoma.
Other cardiovascular disease in Tulsa
- Frank GaffneyTulsa$211K
- Mohamad KhattabTulsa$47K
- Steve KimTulsa$38K
- Eric AuerbachTulsa$35K
- David WilkettTulsa$25K
- Daniel WildesTulsa$24K
- Thomas KalapuraTulsa$17K
- Heather ChaTulsa$16K
- Christopher HigginsTulsa$13K
- Alan KaneshigeTulsa$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.